
Moderna, Inc.
MRNAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 26, 2026 | Piper Sandler | $230.00(+15%) | $200.10 | TheFly | |
| Oct 15, 2026 | Goldman Sachs | Salveen Richter | $137.00(-39%) | $226.30 | TheFly |
| Sep 3, 2026 | UBS | $81.00(-46%) | $150.81 | TheFly | |
| Aug 28, 2026 | Argus Research | John Eade | $180.00(+26%) | $142.77 | StreetInsider |
| Aug 24, 2026 | Barclays | Eliana Merle | $125.00(-14%) | $145.13 | TheFly |
| Aug 20, 2026 | UBS | Michael Yee | $150.00(-14%) | $174.38 | TheFly |
| Aug 19, 2026 | Goldman Sachs | $120.00(-31%) | $174.38 | TheFly | |
| Aug 19, 2026 | RBC Capital | Luca Issi | $130.00(-14%) | $151.30 | TheFly |
| Aug 19, 2026 | Loop Capital Markets | Leah Rush Cann | $135.00(-3%) | $139.12 | StreetInsider |
| Aug 19, 2026 | D.A. Davidson | Michael Baker | $245.00(+77%) | $138.21 | StreetInsider |
| Jul 21, 2026 | Goldman Sachs | $67.00(+13%) | $59.49 | TheFly | |
| Jul 20, 2026 | Wolfe Research | Alexandria Hammond | $25.00(-60%) | $61.82 | StreetInsider |
| Jul 8, 2026 | Morgan Stanley | $39.00(-51%) | $79.77 | TheFly | |
| Jul 7, 2026 | RBC Capital | $45.00(-45%) | $81.80 | TheFly | |
| Jun 26, 2026 | Piper Sandler | $77.00(+14%) | $67.66 | TheFly | |
| May 4, 2026 | UBS | $45.00(-5%) | $47.47 | TheFly | |
| May 4, 2026 | RBC Capital | Luca Issi | $38.00(-19%) | $46.87 | TheFly |
| May 1, 2026 | Goldman Sachs | $49.00(+8%) | $45.37 | TheFly | |
| May 1, 2026 | Morgan Stanley | $33.00(-25%) | $44.18 | TheFly | |
| Mar 3, 2026 | Jefferies | Andrew Tsai | $37.00(-26%) | $49.83 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| William Blair | downgrade | Outperform →Market Perform | Oct 27, 2026 |
| Piper Sandler | maintain | Overweight | Oct 26, 2026 |
| TD Cowen | maintain | Hold | Oct 21, 2026 |
| Goldman Sachs | maintain | Neutral | Oct 15, 2026 |
| Morgan Stanley | maintain | Equal Weight | Oct 7, 2026 |
| Citigroup | downgrade | Neutral →Sell | Sep 30, 2026 |
| Rothschild & Co | downgrade | Neutral →Sell | Sep 3, 2026 |
| Argus Research | upgrade | Hold →Buy | Aug 28, 2026 |
| Wolfe Research | upgrade | Underperform →Peer Perform | Aug 25, 2026 |
| Barclays | maintain | Equal Weight | Aug 24, 2026 |
| JP Morgan | maintain | Underweight | Aug 21, 2026 |
| UBS | maintain | Neutral | Aug 20, 2026 |
| Goldman Sachs | maintain | Neutral | Aug 20, 2026 |
| Morgan Stanley | maintain | Equal Weight | Aug 20, 2026 |
| William Blair | upgrade | Market Perform →Outperform | Aug 19, 2026 |
| Citigroup | maintain | Neutral | Aug 3, 2026 |
| Goldman Sachs | maintain | Neutral | Jul 21, 2026 |
| Morgan Stanley | maintain | Equal Weight | Jul 8, 2026 |
| B of A Securities | maintain | Underperform | Jul 7, 2026 |
| RBC Capital | maintain | Sector Perform | Jul 7, 2026 |
| Piper Sandler | maintain | Overweight | Jun 26, 2026 |
| B of A Securities | maintain | Underperform | Jun 8, 2026 |
| Evercore ISI Group | maintain | In Line | May 4, 2026 |
| Goldman Sachs | maintain | Neutral | May 4, 2026 |
| UBS | maintain | Neutral | May 4, 2026 |
Earnings History
Next report: Feb 12, 2027 · EPS est. $-1.73| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $0.38 | $-1.10 | $1.31B | $890.3M |
| Jul 31, 2026 | $-1.97 | $-2.03 | $145.0M | $102.9M |
| May 1, 2026 | $-3.40 | $-4.45 | $389.0M | $236.4M |
| Feb 13, 2026 | $-2.11 | $-2.54 | $678.0M | $635.2M |
| Nov 6, 2025 | $-0.51 | $-1.87 | $1.02B | $920.9M |
| Aug 1, 2025 | $-2.13 | $-2.99 | $142.0M | $893.3M |
| May 1, 2025 | $-2.52 | $-2.92 | $107.0M | $116.7M |
| Feb 14, 2025 | $-2.50 | $-2.68 | $956.0M | $942.8M |
News
Moderna raised full-year 2026 revenue growth guidance to 15% to 25%. Intismeran reduced the risk of melanoma recurrence or death by 42% in Phase 3.
Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high after delivering much stronger-than-expected Q3 results.
Moderna, Inc. ( MRNA ) Q3 2026 Earnings Call November 6, 2026 8:00 AM EST Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock - Chief Financial Officer Stephen Hoge - President David Berman - Chief Development Officer Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Eliana Merle - Barclays Bank PLC, Research Division Edward Tenthoff - …
Moderna's Q3 earnings beat estimates on strong COVID-19 vaccine sales, returning to profitability and boosting its 2026 revenue growth outlook.
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
Revenue jumped 29% on international COVID vaccine sales tied to long-term government deals. Moderna raised its 2026 revenue growth outlook to 15% to 25%.
BLS results were far better than expected: +165K, close to triple the +59K analysts were looking for.
Moderna NASDAQ: MRNA raised its 2026 revenue growth outlook after reporting higher third-quarter sales and a return to quarterly profitability, as demand for its COVID-19 vaccines and international partnerships supported results.
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
Moderna (NASDAQ:MRNA) stock was last seen up 3.9% to trade at $250.95 after reporting third-quarter earnings of $0.38 per share on $1.3 billion in revenue, versus Wall Street estimates of a loss of $1.25 per share on roughly $882 million in revenue.
Moderna earned a surprise profit in the third quarter, while analysts expected a loss of more than $1 per share. Management raised its full-year revenue growth outlook to 15% to 25% and cut its R&D budget.
Stock futures are trading mixed as Wall Street digests today's nonfarm payrolls data and yesterday's steep selloff
Moderna (MRNA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $1.1 per share. This compares to a loss of $0.51 per share a year ago.
Moderna posts higher-than-expected revenue as results get a lift from international Covid vaccine demand.
The biopharmaceutical company said Friday it now expects total revenue growth of 15% to 25% for the year, compared with a previous outlook for up to 10% growth.
The company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026.
Nov 6 (Reuters) - Moderna (MRNA.
Moderna smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Caldwell Trust Co acquired a new stake in shares of Moderna, Inc. (NASDAQ: MRNA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,541 shares of the company's stock, valued at approximately $1,260,000. A number of other
Moderna, Inc. (NASDAQ:MRNA) will release earnings for its third quarter before the opening bell on Friday, Nov. 6.